For the duration of this retrospective study, Crouse Hospital used alteplase or (recombinant) tissue-type plasminogen activator (r-tPA) as the go to thrombolytic therapy, which has been demonstrated to improve stroke outcomes [28]. This evidence concerns the gene PLAT and stroke disorder.